These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33409784)

  • 21. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
    Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.
    Yamashita S; Takeshima H; Kadota Y; Azuma M; Fukushima T; Ogasawara N; Kawano T; Tamura M; Muta J; Saito K; Takeishi G; Mizuguchi A; Watanabe T; Ohta H; Yokogami K
    Brain Tumor Pathol; 2022 Apr; 39(2):88-98. PubMed ID: 35482260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Jain R; Johnson DR; Patel SH; Castillo M; Smits M; van den Bent MJ; Chi AS; Cahill DP
    Neuro Oncol; 2020 Jul; 22(7):936-943. PubMed ID: 32064507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric-type diffuse low-grade glioma with T2-FLAIR mismatch sign: a case report and literature review.
    Hwa JC; Wong AM; Jung SM; Wu CT
    Childs Nerv Syst; 2024 Aug; 40(8):2271-2278. PubMed ID: 38884778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
    Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
    Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
    Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
    Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign.
    Onishi S; Yamasaki F; Akiyama Y; Kawahara D; Amatya VJ; Yonezawa U; Taguchi A; Ozono I; Khairunnisa NI; Takeshima Y; Horie N
    J Neurooncol; 2024 Nov; 170(2):429-436. PubMed ID: 39133381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
    AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Yamamoto H; Iwaki T; Hiwatashi A; Ishigami K
    Sci Rep; 2022 Jun; 12(1):9197. PubMed ID: 35654812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
    Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W
    Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.